Hynixon pharmaceutical [tamsulosin hydrochloride sustained release capsule] passed the consistency evaluation

On December 31, Qianyuan pharmaceutical released a notice saying that its subsidiary, hynixon pharmaceutical tamsulosin hydrochloride sustained release capsule, passed the consistency evaluation This is the second manufacturer to pass the consistency evaluation of the drug after Hengrui Tamsulosin hydrochloride sustained-release capsule is a kind of sustained-release capsule developed by shannei Pharmaceutical Co., Ltd., which is mainly used for the treatment of urination disorders caused by adult prostate hyperplasia It is currently the first-line main drug for the treatment of the disease, and has been listed in the national medical insurance catalog and the national basic drug catalog It was first approved for sale in Japan in 1993, and the commodity name is Harnal At present, in addition to Hengrui pharmaceutical and hynixon pharmaceutical, the domestic manufacturers of tamsulosin hydrochloride sustained-release capsules include Astaire Pharmaceutical (China), Hangzhou Kangenbei, etc According to the pharmaceutical intelligence data hospital sales data mining system, the sales volume of tamsulosin hydrochloride sustained-release capsule in 2018 was about 227 million yuan Mengmeng's article is the integrated content of yaozhi.com, and the copyright belongs to the original author The purpose of reprint is to transmit more information, which does not represent the view of this platform If the content of the work, copyright and other issues are involved, please contact our website message, we will delete the content in the first time.